Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].

Zhonghua bing li xue za zhi = Chinese journal of pathology - 8 May 2024

Wang S N, Wang W, Zhang X W, Zhang Y Q, Xiong Y L, Liu L, Teng L H

Abstract excerpt

Objective: To examine whether immunohistochemistry of methylthioadenosine phosphorylase (MTAP) and p16 could be used to predict the CDKN2A status in various brain tumors. Methods: A total of 118 cases of IDH-mutant astrocytomas, 16 IDH-wildtype glioblastoma, 17 polymorphic xanthoastrocytoma (PXA) and 20 meningiomas diagnosed at Xuanwu Hospital, Capital Medical University, Beijing, China from November 2017 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Cyclin-Dependent Kinase Inhibitor p16

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioblastoma

Share to In Situ Hybridization, Fluorescence

Share to Isocitrate Dehydrogenase

Share to Meningeal Neoplasms

Share to Meningioma

Share to Purine-Nucleoside Phosphorylase

Source

Identifiers

PMID: 38678323
DOI: 10.3760/cma.j.cn112151-20230815-00069

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].PMID 38678323Read ↗

Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomasSemantic proximity Read ↗

Integrated assessment of malignancy in IDH‐mutant astrocytoma with p16 and methylthioadenosine phosphorylase immunohistochemistrySemantic proximity Read ↗

Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.Semantic proximity Read ↗

Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.Semantic proximity Read ↗

Assessment of CDKN2A homozygous and heterozygous deletions in gliomas across multiple detection platformsSemantic proximity Read ↗

T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant.Semantic proximity Read ↗

Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytomaSemantic proximity Read ↗

Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumorsSemantic proximity Read ↗

MTAP and p16 IHC as Markers for CDKN2A/B Loss in MeningiomasSemantic proximity Read ↗

Methylthioadenosine is Not Dramatically Elevated in <i>MTAP</i> -Homozygous Deleted Primary GlioblastomasSemantic proximity Read ↗

p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic SignificancesSemantic proximity Read ↗

Loss of methylthioadenosine phosphorylase immunoreactivity correlates with poor prognosis and elevated uptake of 11C-methionine in IDH-mutant astrocytoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.